
Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) filed an application with the FDA seeking emergency use authorization for a second booster shot of their COVID-19 vaccine for people aged 65 and older.
An analysis of data from over 1.1 million adults 60 years and older showed rates of confirmed infections were two times lower, and severe illness was four times lower in people who received an additional booster dose administered at least four months after the third dose compared to those with one booster dose.